Expression of melatonin receptor (MT1) and interaction between melatonin and estrogen in endometrial cancer cell line

Journal of Obstetrics and Gynaecology Research

Volumn 34, Issue 4, 2008, Pages 567-573

  Watanabe, Mari ^a   Kobayashi, Yoichi ^a,b   Takahashi, Noriyuki ^a   Kiguchi, Kazushige ^a   Ishizuka, Bunpei ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE   (Japan)

Author keywords

Endometrial cancer; Estrogen; Melatonin; MT1

Indexed keywords

ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; LUZINDOLE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MESSENGER RNA; PACLITAXEL;

ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MONOTHERAPY; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL LINE, TUMOR; ENDOMETRIAL NEOPLASMS; ESTROGENS; FEMALE; HUMANS; MELATONIN; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2;

EID: 50049089344     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2008.00818.x     Document Type: Article

References (33)

1. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: Nature's most versatile biological signal? FEBS J 2006 273 : 2813 2838.
2. Cini G, Neri B, Pacini A et al. Antiproliferative activity of melatonin by transcriptional inhibition of cyclin D1 expression: A molecular basis for melatonin-induced oncostatic effects. J Pineal Res 2005 39 : 12 20.
3. Cos S, Gonzalez A, Martinez-Campa C, Dolores Mediavilla M, Alonso-Gonzalez C, Sanchez-Barcelo EJ. Estrogen-signaling pathway: A link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev 2006 30 : 118 128.
4. Sánchez-Barceló EJ, Cos S, Mediavilla D, Martínez-Campa C, González A, Alonso-González C. Melatonin-estrogen interactions in breast cancer. J Pineal Res 2005 38 : 217 222.
5. Vanecek J. Cellular mechanisms of melatonin action. Phisiol Rev 1998 78 : 687 721.
6. Schneider HP. HRT and cancer risks. Maturitas 2002 30 (Suppl 1 35 52.
7. Ushijima K, Yoshikawa H, Hirakawa T et al. Fertility-sparing treatment by high dose oral medroxyprogesterone acetate for endometrial cancer and atypical hyperplasia in young women: A multi centric phase II study. Proc Am Soc Clin Oncol 2005 23 : 460s 5022).
8. Martin-Hirsch PL, Liford RJ, Jarvis GJ. Adjuvant progestagen therapy for the treatment of endometrial cancer review and meta-analyses of published randomized controlled trials. Eur J Obstet Gynecol Reprod Biol 1996 65 : 201 207.
9. Thigpen JT, Brady MF, Alvarez RD et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma a dose response study by the Gynecologic Oncology Group. J Clin Oncol 1999 17 : 1736 1744.
10. Kanishi Y, Kobayashi Y, Noda S, Ishizuka B, Saito K. Differential growth inhibitory effect of melatonin on two endometrial cancer cell lines. J Pineal Res 2000 28 : 227 233.
11. Kobayashi Y, Itoh MT, Kondo H et al. Melatonin binding sites in estrogen receptor-positive cells derived from human endometrial cancer. J Pineal Res 2003 35 : 71 74.
12. Nishida M. The Ishikawa cells from birth to the present. Hum Cell 2002 15 : 104 117.
13. Furukawa T, Kubota T, Watanabe M et al. High in vitro-in vivo correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end point. Int J Cancer 1992 51 : 489 498.
14. Ohara T, Kiguchi K, Tsukikawa S et al. New chemosensitivity test using a thermo-reversible gelation polymer for recurrent gynecologic cancer patients and a preliminary study of mechanisms of anticancer drug resistance. Hum Cell 2005 18 : 171 180.
15. Witt-Enderby PA, Bennett J, Jarzynka MJ, Firestine S, Melan MA. Melatonin receptors and their regulation: Biochemical and structural mechanisms. Life Sci 2003 72 : 2183 2198.
16. Treeck O, Haldar C, Ortmann O. Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines. Oncol Rep 2006 15 : 231 235.
17. Lanoix D, Ouellette R, Vaillancourt C. Expression of melatoninergic receptors in human placental choriocarcinoma cell lines. Hum Reprod 2006 21 : 1981 1989.
18. Tam CW, Mo CW, Yao KM, Shiu SY. Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22Rv1 human prostate cancer cells: Implications for prostate cancer chemoprevention. J Pineal Res 2007 42 : 191 202.
19. Garcia-Navarro A, Gonzalez-Puga C, Escames G et al. Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. J Pineal Res 2007 43 : 195 205.
20. Aust S, Brucker B, Graf J, Klimpfinger M, Thalhammer T. Melatonin modulates acid/base transport in human pancreatic carcinoma cells. Cell Physiol Biochem 2006 18 : 91 102.
21. Boutin JA, Audinot V, Ferry G, Delagrange P. Molecular tools to study melatonin pathways and actions. Trends Pharmacol Sci 2005 26 : 412 419.
22. Dubocovich ML. Luzindole (N-0774): A novel melatonin receptor antagonist. J Pharmacol Exp Ther 1988 246 : 902 910.
23. Ting KN, Blaylock NA, Sugden D, Delagrange P, Scalbert E, Wilson VG. Molecular and pharmacological evidence for MT1 melatonin receptor subtype in the tail artery of juvenile Wistar rats. Br J Pharmacol 1999 127 : 987 995.
24. Hunt AE, Al-Ghoul WM, Gillette MU, Dubocovich ML. Activation of MT2 melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol Cell Phisiol 2001 280 : C110 C118.
25. Molis TM, Spriggs LL, Hill SM. Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol 1994 8 : 1681 1690.
26. Kiefer T, Ram PT, Yuan L, Hill SM. Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Res Treat 2002 71 : 37 45.
27. Chen C, Chang YC, Liu CL, Chang KJ, Guo IC. Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1. Breast Cancer Res Treat 2006 98 : 121 132.
28. Lissoni P. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol Biol (Paris) 2007 55 : 201 204.
29. Akram T, Maseelall P, Fanning J. Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. Am J Obstet Gynecol 2005 192 : 1365 1367.
30. Regelson W, Pierpaoli W. Melatonin a rediscovered antitumor hormone? Its relation to surface receptors; sex steroid metabolism, immunologic response, and chronobiologic factors in tumor growth and therapy. Cancer Invest 1987 5 : 379 385.
31. Waldhauser F, Ehrhart B, Foster E. Clinical aspects of the melatonin action: Impact of development, aging, and puberty, involvement of melatonin in psychiatric disease and importance of neuroimmunoendocrine interactions. Experientia 1993 49 : 671 681.
32. Hernandez-Diaz FJ, Sanchez JJ, Abreu P et al. Estrogen modulates α1/β adrenoceptor-induced signaling and melatonin production in female rat pinealocytes. Neuroendocrinol 2001 73 : 111 122.
33. Viswanathan AN, Hankinson SE, Schernhammer ES. Night shift work and the risk of endometrial cancer. Cancer Res 2007 67 : 10618 10622.